{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T11:01:05Z","timestamp":1770980465688,"version":"3.50.1"},"reference-count":51,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1016\/j.semarthrit.2010.07.004","type":"journal-article","created":{"date-parts":[[2010,9,17]],"date-time":"2010-09-17T10:23:33Z","timestamp":1284719013000},"page":"398-406","source":"Crossref","is-referenced-by-count":41,"title":["Sustained Clinical Response in Psoriatic Arthritis Patients Treated with Anti-TNF Agents: A 5-year Open-Label Observational Cohort Study"],"prefix":"10.1016","volume":"40","author":[{"given":"Ioanna","family":"Saougou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theodora E.","family":"Markatseli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charalampos","family":"Papagoras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paraskevi V.","family":"Voulgari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yannis","family":"Alamanos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandros A.","family":"Drosos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2010.07.004_bib1","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0049-0172(73)90035-8","article-title":"Psoriatic arthritis","volume":"3","author":"Moll","year":"1973","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2010.07.004_bib2","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0950-3579(05)80193-1","article-title":"Psoriatic arthritis","volume":"9","author":"Gladman","year":"1995","journal-title":"Baillieres Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2010.07.004_bib3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard.2004.032318","article-title":"Classification and diagnostic criteria for psoriatic arthritis","volume":"64","author":"Helliwell","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2010.07.004_bib4","first-page":"2641","article-title":"Epidemiology of psoriatic arthritis in northwest Greece, 1982-2001","volume":"30","author":"Alamanos","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2010.07.004_bib5","first-page":"1354","article-title":"Incidence and prevalence of psoriatic arthritis: a systematic review","volume":"35","author":"Alamanos","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2010.07.004_bib6","first-page":"127","article-title":"Psoriatic arthritis (PSA)\u2014an analysis of 220 patients","volume":"62","author":"Gladman","year":"1987","journal-title":"Q J Med"},{"key":"10.1016\/j.semarthrit.2010.07.004_bib7","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0950-3579(94)80024-3","article-title":"Natural history of psoriatic arthritis","volume":"8","author":"Gladman","year":"1994","journal-title":"Baillieres Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2010.07.004_bib8","first-page":"511","article-title":"Validating the SF-36 health survey questionnaire in patients with psoriatic arthritis","volume":"24","author":"Husted","year":"1997","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2010.07.004_bib9","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/1529-0131(200104)45:2<151::AID-ANR168>3.0.CO;2-T","article-title":"Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis","volume":"45","author":"Husted","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2010.07.004_bib10","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1080\/00015550252948130","article-title":"Quality of life and prevalence of arthritis reported by 5,795 members of the Nordic Psoriasis Associations","volume":"82","author":"Zachariae","year":"2002","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.semarthrit.2010.07.004_bib11","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1002\/art.1780401021","article-title":"Mortality studies in psoriatic arthritis: results from a single outpatient clinic","volume":"40","author":"Wong","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2010.07.004_bib12","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.2165\/00003495-200565090-00004","article-title":"Traditional and newer therapeutic options for psoriatic arthritis: an evidence-based review","volume":"65","author":"Gladman","year":"2005","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.semarthrit.2010.07.004_bib13","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD000212","article-title":"Interventions for psoriatic arthritis","author":"Jones","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.semarthrit.2010.07.004_bib14","article-title":"Interventions for psoriatic arthritis","author":"Jones","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.semarthrit.2010.07.004_bib15","first-page":"1422","article-title":"Therapies for peripheral joint disease in psoriatic arthritis","volume":"33","author":"Soriano","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2010.07.004_bib16","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1093\/rheumatology\/keh514","article-title":"Guideline for anti-TNF-alpha therapy in psoriatic arthritis","volume":"44","author":"Kyle","year":"2005","journal-title":"Rheumatology (Oxford)"},{"issue":"9227","key":"10.1016\/j.semarthrit.2010.07.004_bib17","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","article-title":"Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial","volume":"356","author":"Mease","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2010.07.004_bib18","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1002\/art.20335","article-title":"Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression","volume":"50","author":"Mease","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2010.07.004_bib19","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/art.20967","article-title":"Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)","volume":"52","author":"Antoni","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2010.07.004_bib20","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1136\/ard.2004.032268","article-title":"Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial","volume":"64","author":"Antoni","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2010.07.004_bib21","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1002\/art.21306","article-title":"Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial","volume":"52","author":"Mease","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2010.07.004_bib22","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1136\/ard.2006.058735","article-title":"Infliximab in refractory psoriatic arthritis with severe psoriasis: a 2-year experience","volume":"66","author":"Voulgari","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2010.07.004_bib23","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.semarthrit.2007.07.003","article-title":"Sustained clinical response and high infliximab survival in psoriatic arthritis patients: a 3-year long-term study","volume":"37","author":"Voulgari","year":"2008","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2010.07.004_bib24","first-page":"587","article-title":"Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review","volume":"24","author":"Woolacott","year":"2006","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2010.07.004_bib25","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1002\/art.1780341003","article-title":"The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy","volume":"34","author":"Dougados","year":"1991","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2010.07.004_bib26","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1002\/art.1780391210","article-title":"Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis","volume":"39","author":"Clegg","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2010.07.004_bib27","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000250839","article-title":"Severe psoriasis\u2014oral therapy with a new retinoid","volume":"157","author":"Fredriksson","year":"1978","journal-title":"Dermatologica"},{"key":"10.1016\/j.semarthrit.2010.07.004_bib28","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"Preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2010.07.004_bib29","first-page":"1247","article-title":"The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991","volume":"27","author":"Shbeeb","year":"2000","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2010.07.004_bib30","series-title":"Primer on the rheumatic diseases","first-page":"233","article-title":"Disease modifying antirheumatic drugs","author":"Boumpas","year":"2001"},{"key":"10.1016\/j.semarthrit.2010.07.004_bib31","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1002\/1529-0131(199806)41:6<1103::AID-ART18>3.0.CO;2-N","article-title":"Mortality studies in psoriatic arthritis: results from a single outpatient center","volume":"41","author":"Gladman","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2010.07.004_bib32","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/j.1365-2249.1994.tb06244.x","article-title":"Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions","volume":"96","author":"Ettehadi","year":"1994","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.semarthrit.2010.07.004_bib33","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/1523-1747.ep12337469","article-title":"A TNF-alpha promoter polymorphism is associated with juvenile onset psoriasis and psoriatic arthritis","volume":"109","author":"H\u00f6hler","year":"1997","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.semarthrit.2010.07.004_bib34","first-page":"518","article-title":"Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid","volume":"24","author":"Partsch","year":"1997","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2010.07.004_bib35","first-page":"1544","article-title":"Patterns of cytokine production in psoriatic synovium","volume":"25","author":"Ritchlin","year":"1998","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2010.07.004_bib36","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1002\/1529-0131(200006)43:6<1244::AID-ANR7>3.0.CO;2-2","article-title":"Macrophage-derived cytokine and nuclear factor kappaB p65 expression in synovial membrane and skin of patients with psoriatic arthritis","volume":"43","author":"Danning","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2010.07.004_bib37","first-page":"105","article-title":"Upregulation of cytokine receptors sTNF-R55, sTNF-R75, and sIL-2R in psoriatic arthritis synovial fluid","volume":"25","author":"Partsch","year":"1998","journal-title":"J Rheumatol"},{"issue":"9271","key":"10.1016\/j.semarthrit.2010.07.004_bib38","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/S0140-6736(00)04954-0","article-title":"Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial","volume":"357","author":"Chaudhari","year":"2001","journal-title":"Lancet"},{"issue":"9194","key":"10.1016\/j.semarthrit.2010.07.004_bib39","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","article-title":"Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial","volume":"354","author":"Maini","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2010.07.004_bib40","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","article-title":"Infliximab and methotrexate in the treatment of rheumatoid arthritis Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group","volume":"343","author":"Lipsky","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2010.07.004_bib41","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/art.22331","article-title":"Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study","volume":"56","author":"Hyrich","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2010.07.004_bib42","first-page":"2433","article-title":"Retention rates of tumor necrosis factor blockers in daily practice in 770 rheumatic patients","volume":"33","author":"Duclos","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2010.07.004_bib43","doi-asserted-by":"crossref","first-page":"R72","DOI":"10.1186\/ar1941","article-title":"Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis","volume":"8","author":"Carmona","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2010.07.004_bib44","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/art.23333","article-title":"The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study","volume":"59","author":"Heiberg","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2010.07.004_bib45","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1136\/ard.2007.073544","article-title":"Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register","volume":"67","author":"Kristensen","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2010.07.004_bib46","doi-asserted-by":"crossref","first-page":"R29","DOI":"10.1186\/ar1881","article-title":"Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period","volume":"8","author":"Gomez-Reino","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2010.07.004_bib47","doi-asserted-by":"crossref","first-page":"R52","DOI":"10.1186\/ar2670","article-title":"Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register","volume":"11","author":"Saad","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2010.07.004_bib48","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1136\/ard.61.9.822","article-title":"Infliximab treatment in combination with cyclosporin A in patients with severe refractory rheumatoid arthritis","volume":"61","author":"Temekonidis","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2010.07.004_bib49","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.amjmed.2005.01.029","article-title":"Infliximab therapy in established rheumatoid arthritis: an observational study","volume":"118","author":"Voulgari","year":"2005","journal-title":"Am J Med"},{"key":"10.1016\/j.semarthrit.2010.07.004_bib50","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0065-2776(08)60891-3","article-title":"Anti-tumor necrosis factor-alpha therapy of rheumatoid arthritis","volume":"64","author":"Feldmann","year":"1997","journal-title":"Adv Immunol"},{"key":"10.1016\/j.semarthrit.2010.07.004_bib51","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W","article-title":"Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis","volume":"41","author":"Maini","year":"1998","journal-title":"Arthritis Rheum"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017210001435?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017210001435?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,8]],"date-time":"2018-12-08T02:23:06Z","timestamp":1544235786000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017210001435"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4]]},"references-count":51,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["S0049017210001435"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2010.07.004","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2011,4]]}}}